Inhalable Drugs Market Overview
A Report by DataM Intelligence estimates the Global Inhalable Drugs market to grow at a CAGR of 5.1% during the forecast period 2024-2031. The market is expected to grow because it becomes important in different industries like Respiratory Diseases, Non-Respiratory Diseases. The competitive rivalry intensifies with Sanofi S.A, AstraZeneca., Vectura, and others operating in the market.
Inhalable drugs are broadly used for treating chronic diseases such as COPD, bronchospasm, and asthma and non-respiratory diseases such as diabetes and Parkinson's disease. Medicines that one breathes directly into the lungs are an essential part of treatment for the lungs. The rising incidence of pulmonary diseases has created a lucrative opportunity within the global inhalable drugs market.
Inhalable Drugs Market Scope
| Metrics | Details |
| Market CAGR | 5.1% |
| Segments Covered | By Product, By Application, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights Request Free Sample
Market Dynamics
The increasing prevalence of non-respiratory diseases such as Parkinson’s disease and diabetes is among the essential factors that intensify the inhalable drugs market's growth and demand. The rising geriatric population and advancements in inhalable drug therapies are also contributing to rising in the global market over the forecast period.
The increasing prevalence of non-respiratory diseases is expected to drive the growth in the forecast period
The increasing prevalence of non-respiratory diseases such as diabetes and Parkinson’s disease is a key factor expected to fuel the market for inhalable drugs. Parkinson’s disease is widely reported in people aged 60 years and above. The prevalence rate of this disease increases with age. According to WHO, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population. For instance, in December 2018, INBRIJA, a prescription medicine containing levodopa, was approved by the USFDA for adults.
Advancements in inhalable drugs are expected to propel market growth. Advanced inhalation therapy involves the use of surfactant carriers, nanocrystals, and micro and nanoparticles. Therefore, researches are conducted on small molecules to develop innovative inhalable drugs. These advancements in inhalation therapies offer increased systemic availability of drugs, convenience over invasive methods, improved drug interactions, and minimal toxicities. Reformulation of existing non-inhaled molecules into inhaled molecules for enhanced delivery of the drug is providing new growth opportunities to market players. For instance, reformulation of dihydroergotamine (intravenous drug) into mesylate salt breath-actuated MDI device (Tempo) for treatment of migraine.
The strong presence of leading players in the field is expected to drive the market growth
The strong presence of leading players in the field will continue to benefit the global market. These companies focus on unmet market needs, geographic expansion objectives, developing innovative products, and mergers and acquisitions to capitalize on their market share. These companies also provide services to various entities to improve the quality of drug delivery systems and patient compliance. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of inhalable drugs. Furthermore, these players focus on personnel training and R&D investments to capture a larger share in the market.
Regulatory obstruction is likely to hinder the market growth
However, the high cost of the drugs and stringent government regulations and policies related to drug patents may restrict the growth of the market.
COVID-19 Impact on Inhalable Drugs Market
When a person inhales medication for respiratory-related illnesses, it travels to the airways directly and can potentially be more efficient than taking medicine orally or by injection. However, there are few inhalable drugs to counteract viruses, and none of them targets SARS-CoV-2, the virus that causes COVID-19. The research will develop, optimize inhalable formulations of antiviral drugs, and test them in the lab to assess their suitability. The long-term goal is to prepare inhalable formulations of commercially available antiviral drugs currently in clinical trials for treating lung injury in COVID-19.
SFI is funding a project at the University of Limerick to develop and optimize antiviral drugs so they can be inhaled. The researchers at SSPC, the SFI Research Centre for Pharmaceuticals and PMTC at UL Bernal Institute, Trinity College Dublin, Waterford Institute of Technology, and Teva Pharmaceuticals will test how well the inhalable antiviral drugs target SARS-CoV-2 in the lab, intending to develop inhalable versions of existing antiviral drugs for use in clinical trials against COVID-19.
Market Segment Analysis
The respiratory diseases segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Inhalable drugs are widely used for the treatment of chronic respiratory diseases such as asthma, bronchospasm. The rising rate of pollutants in the air and the release of hazardous gases causing lung diseases including COPD and other respiratory diseases around the world is driving the market. The other factors driving the overall growth include the spread of infections such as tuberculosis and hospital-acquired infection where these tests are used as a preliminary detection tool.
Increasing cases of various infections and chronic diseases such as novel coronavirus and lung disorders among others will also drive the market growth. For instance, about 120,000 patients have already died due to the novel coronavirus outbreak globally and 70% of them are in the European region. As of 16th April 2020, there were more than 1 confirmed case and about 89,338 confirmed deaths according to the WHO in Europe. In the UK, patients were diagnosed with respiratory illnesses. This has increased the patient’s visits to diagnostic centres and hospitals, thus, resulted in high demand for respiratory disease testing market growth. Additionally, the presence of skilled medical professionals is expected to boost the market growth in Europe.
An alarming rise in the level of toxic particles in the air together with the emission of hazardous gases from various sources is accelerating the occurrences of various lung diseases. Besides, urbanization is another prime contributor to asthma as it significantly increases outdoor air pollution. According to the World Health Organization (WHO), around 9 out of every 10 people breathe polluted air, owing to which, nearly seven million deaths occur every year across the globe. Thus, such aforementioned factors are likely to create a wide scope for the growth of the inhalable drug market over the forecast period.
The hospital pharmacy is expected to dominate the Inhalable drugs market during the forecast period
The hospital pharmacies held the largest share in the Inhalable drugs market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Market Geographical Share
North America region holds the largest market share global inhalable drugs market
North America region is dominating the global inhalable drugs market accounted for the largest market share in 2020. The rising prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis is anticipated to boost the market growth. According to the Centers for Disease Control and Prevention (CDC), more than 25 million people were suffering from asthma in the U.S. in 2017, which amounts to approximately 7.7% of the adult population and 8.4% of children. The markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. For instance, in November 2016, Mylan organized the COPD Awareness Month to raise awareness about various treatments (inhaled and other bronchodilators) and their different dosage forms. These factors are driving the market growth in the region.
Companies and Competitive Landscape
The inhalable drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Sanofi S.A, Vectura, Mylan, GlaxoSmithKline, Mundipharma, Boehringer Ingelheim International GmbH, and Cipla Inc., Rockwell Medical Inc, AMAG Pharmaceuticals, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the inhalable drugs market globally.
Market Key Companies to Watch
Sanofi S.A
Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Others. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.
Product Portfolio: The Company’s portfolio is comprised of drugs, generic medicines, food supplements, cosmetics, and medical devices such as cancer, cardiology, gynecology, and diabetes.
The global inhalable drugs market report would provide access to an approx. 61 market data table, 53 figures and 180 pages.
